Pfizer’s Breast Cancer Drug Misses Overall Survival in Study
Pfizer PFE announced disappointing overall survival (OS) results from the phase III PALOMA-3 study. The study showed that the combination of Ibranceand AstraZeneca’s AZN Faslodex (fulvestrant) failed to improve OS compared with Faslodex and placebo in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer whose disease has progressed after prior endocrine therapy. The study is being conducted to assess the efficacy and safety of Ibranceplus Faslodex in women with endocrine therapy-resistant metastatic breast cancer […]